<DOC>
	<DOCNO>NCT00668850</DOCNO>
	<brief_summary>To compare efficacy Generex Oral-lyn™ RapidMist™ System standard regular human insulin therapy measure HbA1c , type-1 diabetes mellitus subject BID NPH intermediate act insulin therapy .</brief_summary>
	<brief_title>Active Comparator Study Generex Oral-lyn™ Spray Injected Human Insulin</brief_title>
	<detailed_description>This 26 week open-label , randomize , multi-center , active comparator study compare oral spray insulin ( Generex Oral-lyn™ ) regular human insulin therapy measure HbA1c , number hypoglycaemic episodes type-1 diabetes mellitus subject . All subject BID NPH intermediate act insulin therapy . If subject use long acting insulin ( Glargine , Detemir , etc . ) , he/she must switch NPH intermediate acting insulin . If insulin analogue ( Novolog , Lispro , Aspart , Aphidra , Glulisine , analogue available subject 's geographical area ) , subject must switch regular human insulin 3 time day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Be male female age 18 75 year Type 1 diabetes mellitus patient ( accord ADA and/or WHO classification ) &gt; 1 year history type 1 DM currently manage daily insulin injection total 0.3 0.8 IU/kg body weight ; Current physical examination , vital sign ECG screen reveals clinically significant abnormality ; Have body mass index ( BMI ) &lt; 27 ; 8.5 % ( inclusively ) &lt; Have glycosylated haemoglobulin HbA1c Willing able follow American Diabetes Association diet guideline type 1 diabetes ; able commit perform home blood glucose monitoring record value well hypoglycemic event Willing give write informed consent prior admission study . Have significant active asthma suspect abnormality buccal mucosa ; cardiovascular , cerebrovascular , hepatic , renal , gastrointestinal , hematological , autoimmune disease ( autoimmune thyroid disease ) ; history athopy drug allergy Have evidence unstable retinopathy ( defined preproliferative proliferative retinopathy currently require photocoagulation therapy ) , nephropathy neuropathy ( gastroparesis orthostatic hypotension ) ; Have hypoglycemia unawareness ; Have one episode severe hypoglycemia seizure coma ketoacidosis within past 12 month ; Have blood pressure excess 160/100 mmHg Screening visit ; Have acute illness within 2 week prior screen ; Have history drug alcohol abuse opinion Investigator would interfere participation protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>